Cubist Pharmaceuticals News

Oil prices fell to near $69 a barrel Monday in Asia amid signs OPEC doesn't plan to cut crude output when it meets next week.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

It seems every day a new lawsuit is popping up that accuses one drugmaker of violating another's patent rights.

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant ...

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc.

Reprints Desk, Inc., and QUOSA, Inc., today announced that Cubist Pharmaceuticals has become the first shared customer to activate integration between Reprints Desk's STM Document Delivery service with QUOSA's Virtual Library, which facilitates copyright-compliant article archiving and scientific literature re-use. The integrated solution features ...

As part of its efforts to expand awareness of the importance of medical progress in the United States, the Pharmaceutical Research and Manufacturers of America is announcing today the addition of seven new member companies.

Canadian drugmaker AEterna Zentaris Inc. said Monday its enlarged prostate drug cetrorelix did not meet its main goal in a late-stage clinical study.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Shares of Cubist Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying he believes Cubist will successfully defend the patents on its antibiotic Cubicin, and expects sales will remain strong.

STOCK MARKETING INC PRESENTS : Capital Gold Corp., Cubist Pharmaceuticals, Inc., Advanced Energy Industries, Inc., Children's Place Retail Stores Inc.

Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program.

FORMA Therapeutics today announced that it has closed on a Series B financing that raised a total of $25.5 million.

SmarTrend, the proprietary pattern recognition system, has made available a free sample copy of our premium research report on at http://www.mysmartrend.com/research/ SmarTrend, our proprietary pattern recognition system, called a Downtrend for Cubist Pharmaceuticals on October 07, 2009 at $18.80. Since then, Cubist Pharmaceuticals has returned ...

Two large development proposals that could boost Lexington's growing reputation as a home for biotechnology are about to come up for a vote.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/03/09, Solos Endoscopy, Inc.

If you think to invest in healthcare industry amid the government controlled reform, you may want to look at Edward Owens a TM Vanguard Healthcare Fund portfolio.

Our analysts have issued complimentary analysis on the following six companies: Seattle Genetics Inc.

TheStreet.com's stock-rating model downgraded design and construction management company AECOM Technology to "sell." The numbers : Fiscal third-quarter net income rose 33% to $51 million and earnings per share climbed 22% to 45 cents, hampered by a higher share count.

Cubist Pharmaceuticals Inc. filed Quarterly Report for the period ended 2009-09-30. Cubist Pharmaceuticals Inc.